Sagent Pharmaceuticals (SGNT) IPO Opens Higher
Tweet
Share
E-mailGet Alerts SGNT Hot Sheet
Join SI Premium – FREE
Sagent Pharmaceuticals (Nasdaq: SGNT) IPO is open for trading. Shares are trading at $18.11 after pricing an up-sized offering of 5,750,000 shares at $16, the high end of the expected $14-$16 range.
Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering.
Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.
Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering.
Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Upgrades Atlassian Corporation (TEAM) to Buy
- Morgan Stanley tracks US drug market prescriptions for week ending July 31
- Papa John\'s (PZZA) PT Lowered to $26 at Jefferies
Create E-mail Alert Related Categories
Hot IPOs, IPOs, Trader TalkRelated Entities
Morgan Stanley, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
